261952-24-3

Usage

Uses

Due to the limited information on the applied potential uses of 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE, it is challenging to list specific applications across different industries. However, based on its classification as a phenylglycine derivative, it can be inferred that 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE may be used in the following ways:
Used in Pharmaceutical Industry:
4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE may be used as an intermediate or building block in the synthesis of pharmaceutical compounds, given its structural similarity to phenylglycine, which is a known component in the development of certain drugs.
Used in Chemical Research:
As a trifluoromethoxy derivative, 4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE could be utilized in chemical research to explore the effects of the trifluoromethoxy group on the properties and reactivity of phenylglycine derivatives, potentially leading to the discovery of new compounds with unique characteristics.
Used in Material Science:
4-(TRIFLUOROMETHOXY)-DL-PHENYLGLYCINE may also find applications in material science, where its specific structural features could be exploited to develop new materials with tailored properties, such as improved stability or enhanced performance in specific applications.

InChI:InChI=1/C9H8F3NO3/c10-9(11,12)16-6-3-1-5(2-4-6)7(13)8(14)15/h1-4,7H,13H2,(H,14,15)

Upstream product

• 659-28-9 p-trifluoromethoxybenzaldehyde 
• 954582-33-3 amino(4-(trifluoromethoxy)phenyl)acetonitrile 

Relevant academic research and scientific papers

Discovery of a novel series of pyrazolo[1,5-a]pyrimidine-based phosphodiesterase 2A inhibitors structurally different from N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the treatment of cognitive disorders

It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in neuropsychiatric and neurodegenerative disorders through augmentation of cyclic nucleotide signaling pathways in brain regions associated with learning and memory. Following our earlier work, this article describes a drug design strategy for a new series of lead compounds structurally distinct from our clinical candidate 2 (TAK-915), and subsequent medicinal chemistry efforts to optimize potency, selectivity over other PDE families, and other preclinical properties including in vitro phototoxicity and in vivo rat plasma clearance. These efforts resulted in the discovery of N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (20), which robustly increased 3′,5′-cyclic guanosine monophosphate (cGMP) levels in the rat brain following an oral dose, and moreover, attenuated MK-801-induced episodic memory deficits in a passive avoidance task in rats. These data provide further support to the potential therapeutic utility of PDE2A inhibitors in enhancing cognitive performance.

HETEROCYCLIC COMPOUND

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Heterocyclic compound

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer’s disease and the like.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.